Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption
| Autor: | Matthew Fair, Pablo Tebas, Emmanouil Papasavvas, Livio Azzoni, Brian N Ross, Karam Mounzer, Daria J. Hazuda, Bonnie J Howell, Jay R. Kostman, Luis J. Montaner |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Demographics medicine.medical_treatment Immunology Human immunodeficiency virus (HIV) HIV Infections Interferon alpha-2 medicine.disease_cause Antiviral Agents Article Polyethylene Glycols Internal medicine PEG ratio medicine Immunology and Allergy Humans Viral suppression business.industry Clinical Studies as Topic Immunotherapy Antiretroviral therapy Recombinant Proteins Infectious Diseases Treatment Outcome Treatment interruption Drug Therapy Combination business |
| Zdroj: | AIDS |
| ISSN: | 1473-5571 0193-5089 |
| Popis: | We report on the post-hoc analysis of three clinical studies (NCT01935089, NCT00594880, and NCT00051818) with chronically HIV-infected, immune-reconstituted individuals with similar entry criteria, and demographics interrupting antiretroviral therapy (ART) without or with 5 weeks of weekly pegylated (Peg)-IFN-α2b or Peg-IFN-α2a immunotherapy added onto ART. Results show similar rates of viral suppression between both immunotherapies when continued during a 4-week ART interruption, despite Peg-IFN-α2a maintaining significantly higher trough blood levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|